Literature DB >> 19190966

Lung cancer as a second primary malignancy: increasing prevalence and its influence on survival.

Silvia Quadrelli1, Gustavo Lyons, Henri Colt, Domingo Chimondeguy, Carlos Silva.   

Abstract

BACKGROUND: The purpose of this study was to review the experience with lung cancer as a second primary malignancy (LCSPM) and to determine whether a history of previous malignancy was an independent prognostic factor in resected non small cell lung cancer (NSCLC).
METHODS: We included 414 patients undergoing pulmonary resection with a curative intention between January 1986 and January 2007. The criteria for classifying a lesion as a lung cancer as a second primary malignancy (LCSPM) were a different histological type or a tumor of identical histological type occurring more than 3 years after treatment of the primary tumor, or separated from the initial primary tumor by more than 2 cm of clinically normal epithelium.
RESULTS: Thirty-four patients (8.2%) had a history of a previous malignancy. LCSPM were more frequent during the last decade (11.4% vs. 3.91%, P = .0009). Breast, uroepithelial, and lung cancer were the most prevalent initial primary tumors. In 64.7% of patients the time interval between the last malignancy and the current lung cancer was 2 years or shorter. Patients with NSCLC and a previous malignancy did not have a significantly different survival rate than patients with the current NSCLC as the first malignancy (5-year survival 65.3% vs. 58.6%, log-rank P = .416).
CONCLUSION: The effectiveness of the surgical resection and the subsequent survival of these patients appear to be well demonstrated, and operative mortality and complications are no higher than for other lung cancer patients.

Entities:  

Mesh:

Year:  2009        PMID: 19190966     DOI: 10.1245/s10434-008-0296-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

1.  Lung cancer patients with a previous extra-pulmonary malignancy should not be considered homogeneous: a clinicopathological analysis of 3530 surgical cases.

Authors:  X-L Hu; S-T Xu; X-C Wang; D-N Hou; C Bao; D Yang; Y-L Song
Journal:  Clin Transl Oncol       Date:  2018-08-21       Impact factor: 3.405

2.  Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice.

Authors:  Martin Faehling; Birgit Schwenk; Sebastian Kramberg; Sabine Fallscheer; Matthias Leschke; Jörn Sträter; Robert Eckert
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-30       Impact factor: 4.553

3.  Reduced E-Cadherin expression is a prognostic biomarker of non-small cell lung cancer: a meta-analysis based on 2395 subjects.

Authors:  Bo Yan; Wei Zhang; Li-Yan Jiang; Wen-Xin Qin; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

4.  Patients with a Previous History of Malignancy Undergoing Lung Cancer Screening: Clinical Characteristics and Radiologic Findings.

Authors:  Darragh F Halpenny; Jane D Cunningham; Niamh M Long; Ramon E Sosa; Michelle S Ginsberg
Journal:  J Thorac Oncol       Date:  2016-05-17       Impact factor: 15.609

5.  The disparity of health facilities in an urban area discourages proposed treatment application in inoperable lung cancer patients.

Authors:  Georgios Hillas; Petros Bakakos; Miltiadis Trichas; Fotis Vlastos
Journal:  Cancer Manag Res       Date:  2010-11-15       Impact factor: 3.989

6.  The burdens of lung cancer involved multiple primary cancers and its occurring patterns-SEER Analysis between 1973 and 2006.

Authors:  Rui Mao; Tao Chen; Fangyu Zhou; Weili Jiang; Xiaorong Yang; Zisheng Ai; Mu Li; Linlin Qin; Long Wang; Ke Fei; Chang Chen
Journal:  Sci Rep       Date:  2017-07-25       Impact factor: 4.379

7.  Long non-coding RNAs may serve as biomarkers in breast cancer combined with primary lung cancer.

Authors:  Xianfeng Ding; Yuhan Zhang; Hongjian Yang; Weimin Mao; Bo Chen; Shifeng Yang; Xiaowen Ding; Dehong Zou; Wenju Mo; Xiangming He; Xiping Zhang
Journal:  Oncotarget       Date:  2017-04-21

8.  Synergistic Antitumor Effect of Oligogalacturonides and Cisplatin on Human Lung Cancer A549 Cells.

Authors:  Cian-Song Huang; Ai-Chun Huang; Ping-Hsiu Huang; Diana Lo; Yuh-Tai Wang; Ming-Chang Wu
Journal:  Int J Mol Sci       Date:  2018-06-14       Impact factor: 5.923

9.  Problems to affect long-term survival for breast cancer patients: An observational study of subsequent lung/bronchus malignancies.

Authors:  Jieqiong Liu; Zheyu Hu; Yuhua Feng; Shan Zeng; Meizuo Zhong
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.